Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Key Findings of the Global Hepatic Encephalopathy Therapeutics Market | Technavio

Technavio Research
Posted on: 13 Feb 18

The latest market research report by Technavio on the global hepatic encephalopathy (HE) therapeutics marketpredicts a CAGR of more than 5% during the period 2018-2022.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180213006049/en/

Technavio has published a new market research report on the global hepatic encephalopathy (HE) therapeutics market from 2018-2022. (Graphic: Business Wire)

The report segments the global hepatic encephalopathy therapeutics market by product (NADs and antibiotics) and by geography (the Americas, EMEA, and APAC). It provides a detailed illustration of the major factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Here are some key findings of the global hepatic encephalopathy therapeutics market, according to Technavio healthcare and life sciences researchers:

  • Availability of co-pay assistance programs: a major market driver
  • Emergence of novel treatment targets: emerging market trend
  • The Americas dominated the global hepatic encephalopathy therapeutics market with close to 43% share in 2017
  • ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, and Valeant Biomet are some of the leading players in this market

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Save more with Technavio. Buy2 reports and get the third for FREE: View all Technavio’s current offers

Availability of co-pay assistance programs: a major market driver

Therapeutics are generally sold at a remarkably higher cost price to provide better profit margins for the drugs. This is done to encourage the vendors as they incur high development cost for the drug. Patients might pay a certain cost, known as co-pay, for the therapeutic and the insurer covers the remaining cost. In several instances, the burden of co-pay has been taken over by the vendors. Such co-pay assistance has a two-pronged impact on the market. It helps in increasing the patient adherence to approved therapies by reducing the adoption of inexpensive alternatives. It also increases the sales volume of therapeutics.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Emergence of novel treatment targets: emerging market trend

At present, lactulose and rifaximin are the most commonly used therapeutics to treat HE. Treatments targeting ammonia production and removal are also emerging in the market. Inflammation is an important factor that is associated with the progression and development of HE. Therefore, there are various treatments that target inflammation. Some of the most recent approaches include the use of probiotics, albumin administration, and dialysis.

According to a senior analyst at Technavio for research oninfectious and rare diseases, “Probiotics reduce the levels of ammonia and endotoxin in the blood by introducing a microorganism into the body. They also reduce inflammation and oxidative stress in hepatocytes. Thus, they can be used in the treatment of HE. Probiotics also provide secondary protection against further episodes through the replacement of urease-producing species with non-urease-producing species. Hence, the emergence of novel treatment targets will drive the growth of the global HE therapeutics market during the forecast period.”

Global market opportunities

The Americas dominated the global hepatic encephalopathy therapeutics market, accounting for a share of approximately 43% during the forecast period. The EMEA region accounted for the second largest share in the market, and the APAC region accounted for the least share in the market. During the forecast period, the highest incremental growth is expected to originate from the Americas.

Big savings with Technavio this February!

 

Get 20% OFF on all Education Technology reports. This offer is valid only till the 28th of this month.

 

OR

 

Celebrate winter sports with 23% OFF all reports in our Outdoor Gear library (Offer valid from Feb 9-25).

 

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180213006049/en/

Business Wire
www.businesswire.com

Last updated on: 13/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.